Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12

Neoplasia (United States)

Volumn 15, Issue 11, 2013, Pages 1262-1271

  Lee, Ming Tsung ^a   Ho, Shuk Mei ^a,b   Tarapore, Pheruza ^a   Chung, Irving ^a   Leung, Yuet Kin ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; CASPASE 7; CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 5; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN BCL 2 L12; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TWO HYBRID SYSTEM; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 7; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR BETA; FEMALE; HEK293 CELLS; HUMANS; MCF-7 CELLS; MUSCLE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84888419560     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131184     Document Type: Article

References (61)

1. Shao W and Brown M (2004). Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 6, 39-52.
2. Schiff R and Osborne CK (2005). Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res 7, 205-211.
3. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven AT, Veldscholte J, Berns EM, Klijn JG, Beex LV, and Foekens JA (2001). Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61, 1721-1733.
4. Droog M, Beelen K, Linn S, and Zwart W (2013). Tamoxifen resistance: from bench to bedside. Eur J Pharmacol 717, 47-57.
5. Hernandez-Aya LF and Gonzalez-Angulo AM (2013). Adjuvant systemic therapies in breast cancer. Surg Clin North Am 93, 473-491.
6. Iwamoto T (2013). Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull 36, 715-718.
7. Welboren WJ, Sweep FC, Span PN, and Stunnenberg HG (2009). Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer 16, 1073-1089.
8. Beelen K, Zwart W, and Linn SC (2012). Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 9, 529-541.
9. Matthews J and Gustafsson JA (2003). Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3, 281-292.
10. Iwao K, Miyoshi Y, Egawa C, Ikeda N, and Noguchi S (2000). Quantitative analysis of estrogen receptor-β mRNA and its variants in human breast cancers. Int J Cancer 88, 733-736.
11. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, and Rochefort H (2001). Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61, 2537-2541.
12. Leygue E, Dotzlaw H, Watson PH, and Murphy LC (1998). Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res 58, 3197-3201.
13. Hodges-Gallagher L, Valentine CD, El Bader S, and Kushner PJ (2008). Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 109, 241-250.
14. Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, and Ortmann O (2008). Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat 110, 507-520.
15. Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, and Hawse JR (2011). Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res 13, R27.
16. Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JÅ, Amado F, Lanari C, and Helguero LA (2013). Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 32, 2390-2402.
17. Mendoza RA, Moody EE, Enriquez MI, Mejia SM, and Thordarson G (2011). Tumorigenicity of MCF-7 human breast cancer cells lacking the p38α mitogenactivated protein kinase. J Endocrinol 208, 11-19.
18. Mendoza RA, Enriquez MI, Mejia SM, Moody EE, and Thordarson G (2011). Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells. J Endocrinol 208, 1-9.
19. Chang EC, Frasor J, Komm B, and Katzenellenbogen BS (2006). Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. Endocrinology 147, 4831-4842.
20. Zampieri L, Bianchi P, Ruff P, and Arbuthnot P (2002). Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. Anticancer Res 22, 2253-2259.
21. Thomas CG, Strom A, Lindberg K, and Gustafsson JA (2011). Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling. Breast Cancer Res Treat 127, 417-427.
22. LaPensee EW, Tuttle TR, Fox SR, and Ben-Jonathan N (2009). Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-α-positive and -negative breast cancer cells. Environ Health Perspect 117, 175-180.
23. Teixeira C, Reed JC, and Pratt MA (1995). Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55, 3902-3907.
24. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, and Bhalla K (1997). Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42, 73-81.
25. Leung YK, Mak P, Hassan S, and Ho SM (2006). Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. Proc Natl Acad Sci USA 103, 13162-13167.
26. Hall JM and McDonnell DP (1999). The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140, 5566-5578.
27. Peng B, Lu B, Leygue E, and Murphy LC (2003). Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30, 13-29.
28. Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, and Liu A (2005). Estrogen receptor α-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERβ1 and ERβ5: potential molecular targets for chemoprevention. Clin Cancer Res 11, 7579-7585.
29. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, et al. (2008). Nuclear and cytoplasmic expression of ERβ1, ERβ2, and ERβ5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14, 5228-5235.
30. Park BW, Kim KS, Heo MK, Yang WI, Kim SI, Kim JH, Kim GE, and Lee KS (2006). The changes of estrogen receptor-β variants expression in breast carcinogenesis: decrease of estrogen receptor-β2 expression is the key event in breast cancer development. J Surg Oncol 93, 504-510.
31. Davies MP, O'Neill PA, Innes H, Sibson DR, Prime W, Holcombe C, and Foster CS (2004). Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrinetreated breast cancer. J Mol Endocrinol 33, 773-782.
32. Stegh AH, Chin L, Louis DN, and DePinho RA (2008). What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 7, 2833-2839.
33. Kouri FM, Jensen SA, and Stegh AH (2012). The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. ScientificWorldJournal 2012, 838-916.
34. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, et al. (2007). Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21, 98-111.
35. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL, and Ho SM (2010). Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 17, 675-689.
36. Lacroix M and Leclercq G (2004). Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83, 249-289.
37. Berglind H, Pawitan Y, Kato S, Ishioka C, and Soussi T (2008). Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line crosscontamination. Cancer Biol Ther 7, 699-708.
38. Leung YK, Lee MT, Lam HM, Tarapore P, and Ho SM (2012). Estrogen receptor-beta and breast cancer: translating biology into clinical practice. Steroids 77, 727-737.
39. La Pensee E Wand Ben-Jonathan N (2010). Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr Relat Cancer 17, R91-R107.
40. Gianni L, Salvatorelli E, and Minotti G (2007). Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7, 67-71.
41. Rabbani A, Finn RM, and Ausió J (2005). The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays 27, 50-56.
42. Fulda S and Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811.
43. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, and Ellisen LW (2007). The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117, 1370-1380.
44. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et al. (2010). Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28, 1145-1153.
45. Berrada N, Delaloge S, and André F (2010). Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol 21(suppl 7), vii30-vii35.
46. Thomadaki H and Scorilas A (2006). BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 43, 1-67.
47. Keen JC and Davidson NE (2003). The biology of breast carcinoma. Cancer 97, 825-833.
48. Yde CW and Issinger OG (2006). Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol 29, 1397-1404.
49. Lukyanova NY, Rusetskya NV, Tregubova NA, and Chekhun VF (2009). Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 31, 87-91.
50. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, et al. (1999). The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13, 1672-1685.
51. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, and Webb P (2000). Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74, 311-317.
52. Shang Y and Brown M (2002). Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468.
53. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, and Schiff R (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95, 353-361.
54. Smith CL, Nawaz Z, and O'Malley BW (1997). Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11, 657-666.
55. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, et al. (1998). Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 12, 1605-1618.
56. Stegh AH and DePinho RA (2011). Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 10, 33-38.
57. Chou CH, Chou AK, Lin CC, Chen WJ, Wei CC, Yang MC, Hsu CM, Lung FW, Loh JK, Howng SL, et al. (2012). GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl. Cell Cycle 11, 532-542.
58. Hong Y, Yang J, Wu W, Wang W, Kong X, Wang Y, Yun X, Zong H, Wei Y, Zhang S, et al. (2008). Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim Biophys Acta 1782, 649-657.
59. Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, and DePinho RA (2008). Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105, 10703-10708.
60. Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP, Protopopov A, Chin L, and DePinho RA (2010). Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 24, 2194-2204.
61. Fuchs Y and Steller H (2011). Programmed cell death in animal development and disease. Cell 147, 742-758